Prevalence of COVID-19 and Psychotropic Drug Treatment in Psychiatric
                    In-patients in Germany in 2020: Results from a Nationwide Pilot
                    Survey

Juliane K. Mueller; Kira F. Ahrens; Michael Bauer; Bernhard T. Baune; Stefan Borgwardt; Jürgen Deckert; Katharina Domschke; Regina Ellwanger; Andreas Fallgatter; Thomas Frodl; Jürgen Gallinat; René Gottschalk; Hans J Grabe; Alkomiet Hasan; Sabine C Herpertz; Rene Hurlemann; Frank Jessen; Joseph Kambeitz; Tilo Kircher; Johannes Kornhuber; Klaus Lieb; Andreas Meyer-Lindenberg; Rainer Rupprecht; Norbert Scherbaum; Christiane Schlang; Anja Schneider; Georg Schomerus; Andreas Thoma; Stefan Unterecker; Martin Walter; Henrik Walter; Andreas Reif; Christine Reif-Leonhard

doi:10.1055/a-2177-3056

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2023; 56(06): 227-238
DOI: 10.1055/a-2177-3056

Original Paper

Prevalence of COVID-19 and Psychotropic Drug Treatment in Psychiatric In-patients in Germany in 2020: Results from a Nationwide Pilot Survey

Juliane K. Mueller

¹Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt/M, Germany

,

Kira F. Ahrens

¹Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt/M, Germany

,

Michael Bauer

⁸Department of Psychiatry and Psychotherapy, Medical Faculty, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany

,

Bernhard T. Baune

¹⁷Department of Psychiatry, University Hospital Münster, University of Münster, Münster, Germany

,

Stefan Borgwardt

¹⁹Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany

,

Jürgen Deckert

¹³Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany

,

Katharina Domschke

¹⁶Department of Psychiatry and Psychotherapy, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

,

Regina Ellwanger

²⁵Health Protection Authority, City of Frankfurt am Main, Germany

,

Andreas Fallgatter

²¹Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health (TüCMH), University of Tübingen, Tübingen, Germany; German Center for Mental Health (DZPG)

,

Thomas Frodl

²³Department of Psychiatry, Otto-von-Guericke University, Magdeburg, Germany

²⁶Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH, University Aachen, Aachen, Germany

,

Jürgen Gallinat

⁴Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

,

René Gottschalk

²⁵Health Protection Authority, City of Frankfurt am Main, Germany

,

Hans J Grabe

¹²Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany

,

Alkomiet Hasan

¹⁰Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg, Augsburg, Germany

,

Sabine C Herpertz

¹⁸Department of General Psychiatry, Center of Psychosocial Medicine, University of Heidelberg, Heidelberg, Germany

,

Rene Hurlemann

²²Department of Psychiatry, School of Medicine & Health Sciences, University of Oldenburg, Oldenburg, Germany

,

Frank Jessen

⁹Department of Psychiatry and Psychotherapy, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

,

Joseph Kambeitz

⁹Department of Psychiatry and Psychotherapy, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

,

Tilo Kircher

¹⁴Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany

,

Johannes Kornhuber

⁶Department of Psychiatry and Psychotherapy, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nuremberg, Germany

,

Klaus Lieb

²Department of Psychiatry and Psychotherapy, University Medical Center Mainz

,

Andreas Meyer-Lindenberg

¹¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

,

Rainer Rupprecht

⁵Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany

,

Norbert Scherbaum

⁷Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, Medical Faculty, University of Duisburg Essen, Essen, Germany

,

Christiane Schlang

²⁵Health Protection Authority, City of Frankfurt am Main, Germany

,

Anja Schneider

²⁰Department of Neurodegeneration and Geriatric Psychiatry, University of Bonn, Bonn, Germany

,

Georg Schomerus

¹⁵Department of Psychiatry and Psychotherapy, Leipzig University Medical Center, Leipzig, Germany

,

Andreas Thoma

¹⁰Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg, Augsburg, Germany

,

Stefan Unterecker

¹³Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany

,

Martin Walter

²⁴Department of Psychiatry and Psychotherapy, University Hospital Jena, Jena, Germany

,

Henrik Walter

³Charité University Clinic Berlin, Freie Universität Berlin, Humboldt- Universität zu Berlin

,

Andreas Reif

¹Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt/M, Germany

,

Christine Reif-Leonhard

¹Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt/M, Germany

› Institutsangaben

Abstract

Introduction In patients with a pre-existing mental disorder, an increased risk for a first manifestation of a psychiatric disorder in COVID-19 patients, a more severe course of COVID-19 and an increased mortality have been described. Conversely, observations of lower COVID-19 incidences in psychiatric in-patients suggested protective effects of psychiatric treatment and/or psychotropic drugs against COVID-19.

Methods A retrospective multi-center study was conducted in 24 German psychiatric university hospitals. Between April and December 2020 (the first and partly second wave of COVID-19), the effects of COVID-19 were assessed on psychiatric in-patient care, the incidence and course of a SARS-CoV-2 infection, and treatment with psychotropic drugs.

Results Patients (n=36,322) were admitted to the hospitals. Mandatory SARS-CoV-2 tests before/during admission were reported by 23 hospitals (95.8%), while 18 (75%) conducted regular testing during the hospital stay. Two hundred thirty-two (0.6%) patients were tested SARS-CoV-2-positive. Thirty-seven (16%) patients were receiving medical treatment for COVID-19 at the psychiatric hospital, ten (4.3%) were transferred to an intermediate/intensive care unit, and three (1.3%) died. The most common prescription for SARS-CoV-2-positive patients was for second-generation antipsychotics (n=79, 28.2%) and antidepressants (SSRIs (n=38, 13.5%), mirtazapine (n=36, 12.9%) and SNRIs (n=29, 10.4%)).

Discussion Contrary to previous studies, our results showed a low number of infections and mortality in SARS-CoV-2-positive psychiatric patients. Several preventive measures seem effective to protect this vulnerable group. Our observations are compatible with the hypothesis of a protective effect of psychotropic drugs against COVID-19 as the overall mortality and need for specific medical treatment was low.

Key words

COVID-19 - psychiatry - psychotropic drugs - SARS-CoV-2

Volltext

Referenzen

References
1 Zhu N, Zhang D, Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733
2 WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. In https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
3 Rogers JP, Chesney E, Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 611-627
4 WHO. The impact of COVID-19 on mental, neurological and substance use services. In: 2020 https://www.who.int/publications/i/item/978924012455
5 Dyall J, Gross R, Kindrachuk J. et al. Middle East respiratory syndrome and severe acute respiratory syndrome: Current therapeutic options and potential targets for novel therapies. Drugs 2017; 77: 1935-1966
6 Zhao YJ, Jin Y, Rao WW. et al. The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: A systematic review and meta-analysis of observational studies. J Affect Disord 2021; 287: 145-157
7 Wade D, Howell D, Beadman M. et al. Characterising neuropsychiatric disorders in patients with COVID-19. Lancet Psychiatry 2020; 7: 933-934
8 Gholami M, Safari S, Ulloa L. et al. Neuropathies and neurological dysfunction induced by coronaviruses. J Neurovirol 2021; 27: 380-396
9 Rogers JP, Chesney E, Oliver D. et al. Psychiatric and neuropsychiatric syndromes and COVID-19 - Authors' reply. Lancet Psychiatry 2020; 7: 664-665
10 Rogers JP, Watson CJ, Badenoch J. et al. Neurology and neuropsychiatry of COVID-19: A systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry 2021; 92: 932-941
11 Taquet M, Luciano S, Geddes JR. et al. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 2021; 8: 130-140
12 Taquet M, Geddes JR, Husain M. et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8: 416-427
13 Rogers JP, David AS. A longer look at COVID-19 and neuropsychiatric outcomes. Lancet Psychiatry 2021; 8: 351-352
14 Klaser K, Thompson EJ, Nguyen LH. et al. Anxiety and depression symptoms after COVID-19 infection: Results from the COVID Symptom Study app. J Neurol Neurosurg Psychiatry 2021; 92: 1254-1258
15 Nalleballe K, Reddy Onteddu S, Sharma R. et al. Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav Immun 2020; 88: 71-74
16 Parra A, Juanes A, Losada CP. et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res 2020; 291: 113254
17 Rentero D, Juanes A, Losada CP. et al. New-onset psychosis in COVID-19 pandemic: A case series in Madrid. Psychiatry Res 2020; 290: 113097
18 Varatharaj A, Thomas N, Ellul MA. et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry 2020; 7: 875-882
19 Vai B, Mazza MG, Delli Colli C. et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: A systematic review and meta-analysis. Lancet Psychiatry 2021; 8: 797-812
20 Toubasi AA, AbuAnzeh RB, Tawileh HBA. et al. A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res 2021; 299: 113856
21 Li L, Li F, Fortunati F. et al. Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection. JAMA Netw Open 2020; 3: e2023282
22 Li L, Roberts SC, Kulp W. et al. Epidemiology, infection prevention, testing data, and clinical outcomes of COVID-19 on five inpatient psychiatric units in a large academic medical center. Psychiatry Res 2021; 298: 113776
23 Fond G, Nemani K, Etchecopar-Etchart D. et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: A systematic review and meta-analysis. JAMA Psychiatry 2021; 78: 1208-1217
24 Fond G, Pauly V, Leone M. et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: A national cohort study. Schizophr Bull 2021; 47: 624-634
25 Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: Analysis from electronic health records in the United States. World Psychiatry 2021; 20: 124-130
26 Nemani K, Li C, Olfson M. et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry 2021; 78: 380-386
27 Balaram K, Marwaha R, Kaelber DC. The effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes. Curr Opin Psychiatry 2021; 34: 386-392
28 Maripuu M, Bendix M, Ohlund L. et al. Death associated with coronavirus (COVID-19) infection in individuals with severe mental disorders in Sweden during the early months of the outbreak-an exploratory cross-sectional analysis of a population-based register study. Front Psychiatry 2020; 11: 609579
29 Taquet M, Harrison PJ. Why is COVID-19 associated with mental illness. Med (N Y) 2021; 2: 899-902
30 Moni MA, Lin PI, Quinn JMW. et al. COVID-19 patient transcriptomic and genomic profiling reveals comorbidity interactions with psychiatric disorders. Transl Psychiatry 2021; 11: 160
31 Quincozes-Santos A, Rosa RL, Tureta EF. et al. COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders. Brain Behav Immun Health 2021; 11: 100196
32 Song E, Zhang C, Israelow B. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 2021; 218
33 Raony I, de Figueiredo CS, Pandolfo P. et al. Psycho-neuroendocrine-immune interactions in COVID-19: Potential impacts on mental health. Front Immunol 2020; 11: 1170
34 Tang SW, Helmeste D, Leonard B. Inflammatory neuropsychiatric disorders and COVID-19 neuroinflammation. Acta Neuropsychiatr 2021; 33: 165-177
35 Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: Consequence or mediator of therapeutic effects in psychiatric treatment. Psychopharmacology (Berl) 2016; 233: 1575-1589
36 Meyer JH, Cervenka S, Kim MJ. et al. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry 2020; 7: 1064-1074
37 Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: Depression fans the flames and feasts on the heat. Am J Psychiatry 2015; 172: 1075-1091
38 Kohler CA, Freitas TH, Stubbs B. et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol Neurobiol 2018; 55: 4195-4206
39 Troubat R, Barone P, Leman S. et al. Neuroinflammation and depression: A review. Eur J Neurosci 2021; 53: 151-171
40 Muller N. Inflammation in Schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophr Bull 2018; 44: 973-982
41 Plaze M, Attali D, Petit AC. et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale 2020; 46: 169-172
42 Dobre D, Schwan R, Jansen C. et al. Clinical features and outcomes of COVID-19 patients hospitalized for psychiatric disorders: A French multi-centered prospective observational study. Psychol Med 2021; 1-9
43 Villoutreix BO, Beaune PH, Tamouza R. et al. Prevention of COVID-19 by drug repurposing: Rationale from drugs prescribed for mental disorders. Drug Discov Today 2020; 25: 1287-1290
44 Canal-Rivero M, Catalan-Barragan R, Rubio-Garcia A. et al. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population. Schizophr Res 2021; 229: 53-54
45 Canal-Rivero M, Catalan-Barragan R, Rubio-Garcia A. et al. The role of antipsychotics against COVID-19: A topic for debate. Schizophr Res 2021; 235: 5-6
46 Hoertel N, Sanchez-Rico M, Vernet R. et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Mol Psychiatry 2021; 26: 5199-5212
47 Min KH, Kim TH, Oh SJ. et al. COVID-19 prognosis in association with antidepressant use. Pharmacopsychiatry 2022; 55: 220-227
48 Mueller JK, Riederer P, Muller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence?. Pharmacopsychiatry 2022; 55: 7-15
49 Creeden JF, Imami AS, Eby HM. et al. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomed Pharmacother 2021; 138: 111437
50 Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19. JAMA Netw Open 2021; 4: e2136510
51 Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci 2022; 272: 161-163
52 Lenze EJ, Mattar C, Zorumski CF. et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020; 324: 2292-2300
53 Reis G, Dos Santos Moreira-Silva EA, Silva DCM. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022; 10: e42-e51
54 Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis 2021; 8: ofab050
55 Main Fa https://frankfurt.de/-/media/frankfurtde/service-und-rathaus/zahlen-daten-fakten/pdf/pdf-fsa/2021/fsa_2021_07_bevoelkerung_ende2020.ashx In: Frankfurt Statistik.aktuell: 2021
56 Wagner R, Peterhoff D, Beileke S. et al. Estimates and determinants of SARS-Cov-2 seroprevalence and infection fatality ratio using latent class analysis: The population-based Tirschenreuth Study in the Hardest-Hit German County in spring 2020. Viruses 2021; 13
57 Hoertel N, Sanchez-Rico M, Herrera-Morueco JJ. et al. Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: Results from 49,089 COVID-19 inpatients. Mol Psychiatry 2022; 27: 1278-1280
58 Simpson SA, Loh RM, Cabrera M. et al. The impact of the COVID-19 pandemic on psychiatric emergency service volume and hospital admissions. J Acad Consult Liaison Psychiatry 2021; 62: 588-594
59 Aly L, Sondergeld R, Holzle P. et al. The COVID-19 pandemic has not changed the number but the type of psychiatric emergencies: A comparison of care data between 2019 and 2020. Nervenarzt 2020; 91: 1047-1049
60 Hoyer C, Ebert A, Szabo K. et al. Decreased utilization of mental health emergency service during the COVID-19 pandemic. Eur Arch Psychiatry Clin Neurosci 2021; 271: 377-379
61 Fasshauer JM, Bollmann A, Hohenstein S. et al. Emergency hospital admissions for psychiatric disorders in a German-wide hospital network during the COVID-19 outbreak. Soc Psychiatry Psychiatr Epidemiol 2021; 56: 1469-1475
62 Clerici M, Durbano F, Spinogatti F. et al. Psychiatric hospitalization rates in Italy before and during COVID-19: did they change? An analysis of register data. Ir J Psychol Med 2020; 37: 283-290
63 Goldenberg MN, Parwani V. Psychiatric emergency department volume during Covid-19 pandemic. Am J Emerg Med 2021; 41: 233-234
64 Pignon B, Gourevitch R, Tebeka S. et al. Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. Psychiatry Clin Neurosci 2020; 74: 557-559
65 Montes JM, Hernandez-Huerta D. Impact of the COVID-19 pandemic on acute inpatient psychiatric units in Spain. Psychiatry Res 2021; 304: 114136
66 Adorjan K, Pogarell O, Probstl L. et al. Impact of the COVID-19 pandemic on the care situation in psychiatric hospitals in Germany. Nervenarzt 2021; 92: 562-570
67 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242
68 Fasshauer JM, Bollmann A, Hohenstein S. et al. Psychiatric emergency admissions and inpatient length of stay before and during the COVID-19 pandemic in Germany. Psychiatr Prax 2022; 49: 271-275
69 [Anonymous] https://de.statista.com/statistik/daten/studie/1102667/umfrage/erkrankungs-und-todesfaelle-aufgrund-des-coronavirus-in-deutschland/ 2022
70 Ji W, Huh K, Kang M. et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci 2020; 35: e237
71 Wang QQ, Kaelber DC, Xu R. et al. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol Psychiatry 2021; 26: 30-39
72 Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 2020; 7: e21
73 Lee SW, Yang JM, Moon SY. et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: A nationwide cohort study. Lancet Psychiatry 2020; 7: 1025-1031
74 Ayling K, Jia R, Coupland C. et al. Psychological predictors of self-reported COVID-19 outcomes: Results from a prospective cohort study. Ann Behav Med 2022; 56: 484-497
75 Chevance A, Gourion D, Hoertel N. et al. Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review. Encephale 2020; 46: 193-201
76 Knowles M, Aref-Adib G, Moslehi S. et al. Containing COVID: the establishment and management of a COVID-19 ward in an adult psychiatric hospital. BJPsych Open 2020; 6: e140
77 Bocher R, Jansen C, Gayet P. et al. Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic. Encephale 2020; 46: S81-S84
78 Percudani M, Corradin M, Moreno M. et al. Mental health services in Lombardy during COVID-19 outbreak. Psychiatry Res 2020; 288: 112980
79 Hoertel N, Sanchez-Rico M, Muela P. et al. Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: An observational multicenter study in France. Biol Psychiatry Glob Open Sci 2022;
80 Steardo L, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry 2020; 10: 261
81 Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: Double trouble. Neuron 2020; 107: 234-256
82 Benedetti F, Aggio V, Pratesi ML. et al. Neuroinflammation in bipolar depression. Front Psychiatry 2020; 11: 71
83 Bonnet U, Juckel G, Scherbaum N. et al. Are persons treated with antidepressants and/or antipsychotics possibly better protected against severe COVID 19. Pharmacopsychiatry 2021; 54: 142-143
84 Javelot H, Petrignet J, Addiego F. et al. Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances. Med Hypotheses 2020; 144: 110025
85 Stip E, Rizvi TA, Mustafa F. et al. The large action of chlorpromazine: Translational and transdisciplinary considerations in the face of COVID-19. Front Pharmacol 2020; 11: 577678
86 Bonnet U, Claus B, Schaefer M. et al. Impact of psychiatric and related somatic medications on the duration and severity of COVID-19: A retrospective explorative multi-center study from the German Metropolitan Ruhr-area. Pharmacopsychiatry 2022; 55: 30-39
87 Rivas-Ramirez AR, Tendilla-Beltran H, Gomez-Mendoza LE. et al. Patients with schizophrenia have decreased COVID-19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population. Int J Clin Pract 2021; 75: e14528
88 Moga S, Teodorescu A, Ifteni P. et al. Inflammatory response in SARS-CoV-2 infection of patients with schizophrenia and long-term antipsychotic treatment. Neuropsychiatr Dis Treat 2021; 17: 3053-3060
89 Oskotsky T, Maric I, Tang A. et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open 2021; 4: e2133090
90 Clelland CL, Ramiah K, Steinberg L. et al. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open 2021; 8: e6
91 Bonnet U, Juckel G. COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-a scoping review. J Clin Psychopharmacol 2022; 42: 284-292
92 Obiora E, Hubbard R, Sanders RD. et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: A nested case-control and survival analysis in a population-based cohort. Thorax 2013; 68: 163-170
93 Hoertel N, Sanchez-Rico M, Gulbins E. et al. Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: A multicentre observational study. Epidemiol Psychiatr Sci 2022; 31: e18
94 Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry 2022; 27: 307-314
95 Hoertel N, Sanchez-Rico M, Gulbins E. et al. Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: An observational multicenter study. Transl Psychiatry 2022; 12: 90
96 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395: 1054-1062
97 Barcella CA, Polcwiartek C, Mohr GH. et al. Severe mental illness is associated with increased mortality and severe course of COVID-19. Acta Psychiatr Scand 2021; 144: 82-91
98 D'Andrea G, Pascale R, Vatamanu O. et al. Exposure to psychotropic medications and COVID-19 course after hospital admission: Results from a prospective cohort study. J Psychosom Res 2023; 167: 111199
99 Docherty AB, Harrison EM, Green CA. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 2020; 369: m1985
100 Richardson S, Hirsch JS, Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; 323: 2052-2059
101 Petrilli CM, Jones SA, Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ 2020; 369: m1966
102 Racki V, Marcelic M, Stimac I. et al. Effects of haloperidol, risperidone, and aripiprazole on the immunometabolic properties of BV-2 microglial cells. Int J Mol Sci 2021; 22
103 Mosiolek A, Pieta A, Jakima S. et al. Effects of antidepressant treatment on peripheral biomarkers in patients with major depressive disorder (MDD. J Clin Med 2021; 10

Zusatzmaterial

Supplementary Material